About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights

By: via GlobeNewswire

EXTON, PA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a vast patient population and significant unmet need. Highly anticipated by the field, this milestone is expected to transform the future of MASH care. 

Findings from a Spherix Global Insights pulse study among gastroenterologists and hepatologists (n=77) conducted one week after the announcement revealed that only 42% of physicians reported unaided awareness of Wegovy’s approval. However, this modest initial awareness has not dampened enthusiasm. Nearly two-thirds (65%) of physicians expect to prescribe Wegovy within the next three months, underscoring strong confidence in the therapy’s role in addressing MASH. 

Wegovy enters a market currently defined by Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved therapy for MASH. With more than a year’s head start, Rezdiffra has helped drive disease awareness and has established a strong adoption base, with most specialists already prescribing and planning to expand use. Insights from Spherix’ Launch Dynamix™: Rezdiffra in MASH series confirm that momentum for Rezdiffra remains robust. 

The pulse study also further underscores the distinct roles physicians envision for the two therapies. For patients with moderate fibrosis (F2), Wegovy monotherapy emerged as the leading approach, with 43% of physicians preferring it, citing weight loss as a powerful driver of improvements in liver fat, fibrosis, and overall metabolic health. Rezdiffra monotherapy also demonstrated notable appeal in this group, with 30% of physicians preferring it based on its demonstrated antifibrotic efficacy. As one physician noted, “Wegovy causes weight loss, and weight loss is critical to reduce liver fat, liver fibrosis, and importantly the progression from F2 to F3 in MASH patients.” Another added, “By targeting weight loss, Wegovy will reverse the underlying pathology and help the patients’ comorbidities.” 

For advanced fibrosis (F3) patients, the treatment preferences shift toward combination therapy. The pairing of Rezdiffra and Wegovy was the most common preference, selected by 43% of physicians who expressed skepticism that monotherapy alone could adequately treat this high-risk population. One specialist explained, “We have known for several years that monotherapy is less likely to be the final answer for Advanced MASH liver disease. The combination of Rezdiffra and Wegovy offers the possibility of preventing that progression, at least until we have more effective monotherapy.” 

With early prescribing intent trending positively and physicians already identifying clear positioning for Wegovy across patient segments, the therapy is positioned to make a substantial impact in MASH care. Spherix Global Insights will continue to monitor Wegovy’s trajectory, tracking prescriber sentiment, adoption, and evolving treatment strategies in the months ahead.  

Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. 

About Spherix Global Insights   

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.   

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.   

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.   

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.   

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com    

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.


Jim Hickey, Gastroenterology Franchise Head
Spherix Global Insights
4848794284
james.hickey@spherixglobalinsights.com

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.